Suicidal overdose of dolutegravir: A case report"

Abstract

Dolutegravir (DTG) is the most recently introduced integrase inhibitor for the treatment of HIV infection and is preferred for its superior tolerability and efficacy in both new and pre- treated patients, and infrequent drug interactions. Since January 2017, Botswana has adopted a 'treat-air approach with a DTC-based antiretroviral (ARV) regimen as first-line treatment. We report a 29-year-old man with clinical stage 1 IIIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg of DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum creatinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect 2018. The Authors.